Eli Lilly shutters the last PhIII sola study, certain of failure
Eli Lilly has taken another big reverse step in its retreat from solanezumab, the Alzheimer’s drug once considered the company’s lottery ticket in R&D.
Following the failure of Expedition 3, Lilly’s massively expensive third attempt to come up with solid data of its efficacy, investigators have now washed their hands of Expedition Pro, another Phase III study mounted for patients with prodomal disease, when their memory begins to fade but they can still function well on a daily basis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.